NCT04129736View on ClinicalTrials.gov

Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

June 30, 2021

Conditions
Multiple Sclerosis, Pharmacokinetics
Interventions
DRUG

Teriflunomide 14 MG

Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis

Trial Locations (1)

41345

MS Centre, Gothenburg

All Listed Sponsors
lead

Jan Lycke

OTHER

NCT04129736 - Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter